Metabolic Biomarkers in Cancer: Linking Metabolism to Tumor Progression and Therapeutic Targets
Abstract
Cancer is a multifaceted disease characterized by profound metabolic reprogramming, which enables tumor cells to sustain rapid proliferation, evade apoptosis, and adapt to microenvironmental stresses. Metabolic biomarkers have emerged as critical tools for understanding tumor biology, aiding in early diagnosis, monitoring disease progression, and guiding therapeutic interventions. This review explores the role of metabolic biomarkers in linking altered cellular metabolism to tumor progression and therapeutic targeting. Hallmarks of cancer metabolism, such as the Warburg effect, glutaminolysis, and lipid metabolism dysregulation, produce distinct metabolic byproducts that serve as potential biomarkers. Key metabolites, including lactate, glutamine, and lipid derivatives, reflect the metabolic demands of tumor cells and their interaction with the tumor microenvironment. Advances in metabolomics and imaging techniques have facilitated the identification of these biomarkers, providing insights into tumor heterogeneity and metabolic vulnerabilities. Moreover, metabolic biomarkers are increasingly being utilized to predict treatment response and resistance. For instance, elevated levels of lactate and hypoxia-inducible factor-1α (HIF-1α) correlate with poor prognosis and resistance to conventional therapies. Targeting metabolic pathways, such as glycolysis inhibitors or glutaminase inhibitors, has shown promise in preclinical and clinical studies, underscoring the therapeutic potential of disrupting tumor metabolism. This review highlights the clinical utility of metabolic biomarkers as diagnostic and prognostic tools, while also emphasizing their role in developing targeted therapies. By integrating metabolic profiling into precision oncology, these biomarkers hold the potential to improve patient outcomes and personalize cancer treatment strategies. Further research is essential to validate their application across diverse cancer types and therapeutic settings.
References
J. Han, Q. Li, Y. Chen, and Y. Yang, "Recent metabolomics analysis in tumor metabolism reprogramming," Front. Mol. Biosci., vol. 8, 2021. [Online]. Available: https://frontiersin.org/articles/10.3389/fmolb.2021.737490/full.
X. Wu, Z. Wang, L. Luo, D. Shu, and K. Wang, "Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine," Front. Med. Technol., vol. 4, p. 1065506, 2023. [Online]. Available: https://frontiersin.org/articles/10.3389/fmedt.2023.1065506/full.
L. Wan et al., "Circulating tumor cell and metabolites as novel biomarkers for early-stage lung cancer diagnosis," Front. Oncol., vol. 11, p. 630672, 2021. [Online]. Available: https://frontiersin.org/articles/10.3389/fonc.2021.630672/full.
L. L. Cao et al., "Metabolic profiling identified a novel biomarker panel for metabolic syndrome-positive hepatocellular cancer," Front. Endocrinol., vol. 12, p. 816748, 2022. [Online]. Available: https://frontiersin.org/articles/10.3389/fendo.2021.816748/full.
Y. W. Kwon et al., "Application of proteomics in cancer: recent trends and approaches for biomarkers discovery," Front. Med., vol. 8, p. 747333, 2021. [Online]. Available: https://frontiersin.org/articles/10.3389/fmed.2021.747333/full.
M. M. Pinto et al., "The Warburg effect and mitochondrial oxidative phosphorylation: Friends or foes?," Biochim. Biophys. Acta (BBA)-Bioenerg., vol. 1864, no. 1, p. 148931, 2023. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S0005272820301509.
P. Vaupel and G. Multhoff, "Revisiting the Warburg effect: historical dogma versus current understanding," J. Physiol., vol. 599, no. 6, pp. 1547-1554, 2021. [Online]. Available: https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/JP279134.
S. Cassim, M. Vučetić, M. Ždralević, and J. Pouyssegur, "Warburg and beyond: the power of mitochondrial metabolism to collaborate or replace fermentative glycolysis in cancer," Cancers, vol. 12, no. 10, p. 2965, 2020. [Online]. Available: https://www.mdpi.com/2072-6694/12/10/2965.
S. Bose, C. Zhang, and A. Le, "Glucose metabolism in cancer: The Warburg effect and beyond," Adv. Exp. Med. Biol., vol. 1311, pp. 181-202, 2021. [Online]. Available: https://oapen.org/record/407524.
H. Mirzaei and M. R. Hamblin, "Regulation of glycolysis by non-coding RNAs in cancer: switching on the Warburg effect," Mol. Ther.-Oncolytics, vol. 19, pp. 367-380, 2020. [Online]. Available: https://www.cell.com/molecular-therapy-oncolytics/fulltext/S2352-5738(20)30060-1.
F. Danzi et al., "To metabolomics and beyond: a technological portfolio to investigate cancer metabolism," Signal Transduct. Target. Ther., vol. 8, no. 1, p. 137, 2023. [Online]. Available: https://www.nature.com/articles/s41392-023-01292-2.
N. Dalal et al., "Omics technologies for improved diagnosis and treatment of colorectal cancer: Technical advancement and major perspectives," Biomed. Pharmacother., vol. 131, p. 110648, 2020. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0753332220301909.
Ullah et al., "Multi-omics approaches in colorectal cancer screening and diagnosis, recent updates and future perspectives," Cancers, vol. 14, no. 9, p. 2302, 2022. [Online]. Available: https://www.mdpi.com/2072-6694/14/9/2302.
M. Rienzo et al., "High-throughput screening for high-efficiency small-molecule biosynthesis," Metab. Eng., vol. 63, pp. 102-125, 2021. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S1096717620300729.
D. R. Schmidt et al., "Metabolomics in cancer research and emerging applications in clinical oncology," CA: Cancer J. Clin., vol. 71, no. 4, pp. 333-358, 2021. [Online]. Available: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21685.
J. Eniafe and S. Jiang, "The functional roles of TCA cycle metabolites in cancer," Oncogene, 2021. [Online]. Available: https://www.nature.com/articles/s41388-021-01597-0.
S. Paul, S. Ghosh, and S. Kumar, "Tumor glycolysis, an essential sweet tooth of tumor cells," Semin. Cancer Biol., 2022. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S1044579X22001479.
M. Tufail, C. H. Jiang, and N. Li, "Altered metabolism in cancer: Insights into energy pathways and therapeutic targets," Mol. Cancer, vol. 23, p. 17, 2024. [Online]. Available: https://link.springer.com/article/10.1186/s12943-024-01728-4.
C. Schiliro and B. L. Firestein, "Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation," Cells, vol. 10, no. 11, p. 3019, 2021. [Online]. Available: https://www.mdpi.com/2073-4409/10/11/3019.
R. Kumar et al., "Metabolic pathways, enzymes, and metabolites: Opportunities in cancer therapy," Cancers, vol. 14, no. 21, p. 5268, 2022. [Online]. Available: https://www.mdpi.com/2072-6694/14/21/5268.
Ruiz-Iglesias and S. Mañes, "The importance of mitochondrial pyruvate carrier in cancer cell metabolism and tumorigenesis," Cancers, vol. 13, no. 7, p. 1457, 2021. [Online]. Available: https://www.mdpi.com/2072-6694/13/7/1457.
G. Colleluori, J. Perugini, G. Barbatelli, and S. Cinti, "Mammary gland adipocytes in lactation cycle, obesity and breast cancer," Rev. Endocr. Metab. Disord., vol. 22, pp. 241-255, 2021. [Online]. Available: https://link.springer.com/article/10.1007/s11154-021-09659-x.
K. A. Brown, "Metabolic pathways in obesity-related breast cancer," Nat. Rev. Endocrinol., vol. 17, no. 2, pp. 88-99, 2021. [Online]. Available: https://www.nature.com/articles/s41574-020-00406-4.
Sánchez et al., "Breast milk: A source of functional compounds with potential application in nutrition and therapy," Nutrients, vol. 13, no. 3, p. 1026, 2021. [Online]. Available: https://www.mdpi.com/2072-6643/13/3/1026.
C. Masi and C. J. Stewart, "Role of breastfeeding in disease prevention," Microb. Biotechnol., vol. 17, no. 1, pp. 84-95, 2024. [Online]. Available: https://onlinelibrary.wiley.com/doi/full/10.1111/1751-7915.13998.
H. Xu et al., "Inhibitory effects of breast milk-derived Lactobacillus rhamnosus Probio-M9 on colitis-associated carcinogenesis by restoration of the gut microbiota in a mouse model," Nutrients, vol. 13, no. 4, p. 1143, 2021. [Online]. Available: https://www.mdpi.com/2072-6643/13/4/1143.
Kalbermatter, N. Fernandez Trigo, S. Christensen, and S. C. Ganal-Vonarburg, "Maternal microbiota, early life colonization and breast milk drive immune development in the newborn," Front. Immunol., vol. 12, p. 683022, 2021. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2021.683022/full.
M. Hannan, T. Elajnaf, L. N. Vandenberg, S. H. Kennedy, and R. V. Thakker, "Hormonal regulation of mammary gland development and lactation," Nat. Rev. Endocrinol., vol. 19, no. 1, pp. 46-61, 2023. [Online]. Available: https://www.yayavro.com/article/10.1038/s41574-022-00689-7.
L. P. Fernández, M. Gomez de Cedron, and A. Ramirez de Molina, "Alterations of lipid metabolism in cancer: implications in prognosis and treatment," Front. Oncol., vol. 10, p. 577420, 2020. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fonc.2020.577420/full.
Azam and N. E. Sounni, "Lipid metabolism heterogeneity and crosstalk with mitochondria functions drive breast cancer progression and drug resistance," Cancers, vol. 14, no. 11, p. 3275, 2022. [Online]. Available: https://www.mdpi.com/2072-6694/14/11/3275.
H. Li, Z. Feng, and M. L. He, "Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells," Theranostics, vol. 10, no. 23, pp. 10112-10125, 2020. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650071/.
L. Wang, S. Zhang, and X. Wang, "The metabolic mechanisms of breast cancer metastasis," Front. Oncol., vol. 11, p. 758358, 2021. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fonc.2021.758358/full.
X. Li, M. Liu, H. Liu, and J. Chen, "Tumor metabolic reprogramming in lung cancer progression," Oncol. Lett., vol. 23, no. 2, p. 59, 2022. [Online]. Available: https://www.spandidos-publications.com/ol/23/2/59.
Z. Wang, X. Wu, H. N. Chen, and K. Wang, "Amino acid metabolic reprogramming in tumor metastatic colonization," Front. Oncol., vol. 13, p. 1030936, 2023. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fonc.2023.1030936/full.
R. Xu et al., "Reprogramming of amino acid metabolism in pancreatic cancer: recent advances and therapeutic strategies," Front. Oncol., vol. 10, p. 572722, 2020. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fonc.2020.572722/full.
X. Luo, J. Liu, H. Wang, and H. Lu, "Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis," Pharmacol. Res., 2020. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S1043661820302370.
S. Qiu et al., "Small molecule metabolites: discovery of biomarkers and therapeutic targets," Signal Transduct. Target. Ther., vol. 8, no. 1, p. 132, 2023. [Online]. Available: https://www.nature.com/articles/s41392-023-01297-x.
S. Gheorghe et al., "Biochemical and metabolical pathways associated with microbiota-derived butyrate in colorectal cancer and omega-3 fatty acids implications: A narrative review," Nutrients, vol. 14, no. 6, p. 1152, 2022. [Online]. Available: https://www.mdpi.com/2072-6643/14/6/1152.
J. Li, A. Zhang, F. Wu, and X. Wang, "Alterations in the gut microbiota and their metabolites in colorectal cancer: recent progress and future prospects," Front. Oncol., vol. 12, p. 720095, 2022. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fonc.2022.720095/full.
X. Guo et al., "Gut microbiota and serum metabolite signatures along the colorectal adenoma-carcinoma sequence: Implications for early detection and intervention," Clin. Chim. Acta, 2024. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S0009898124000397.
Russo et al., "From adenoma to CRC stages: the oral-gut microbiome axis as a source of potential microbial and metabolic biomarkers of malignancy," Neoplasia, vol. 40, p. 100901, 2023. [Online]. Available: https://www.sciencedirect.com/science/article/abs/pii/S1476536220301312.
Genua et al., "Association of circulating short chain fatty acid levels with colorectal adenomas and colorectal cancer," Clin. Nutr. ESPEN, vol. 46, pp. 297-304, 2021. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S2405452620301362.
Y. Gong et al., "Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets," Cell Metabolism, vol. 33, no. 1, pp. 51-64, 2021. [Online]. Available: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30558-2.
Elia and M. C. Haigis, "Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism," Nat. Metab., vol. 3, no. 1, pp. 27-37, 2021. [Online]. Available: https://www.nature.com/articles/s41591-020-00864-w.
Z. E. Stine et al., "Targeting cancer metabolism in the era of precision oncology," Nat. Rev. Drug Discov., vol. 21, no. 2, pp. 141-162, 2022. [Online]. Available: https://www.nature.com/articles/s41573-021-00190-6.
J. Han et al., "Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma," Int. J. Cancer, vol. 146, no. 6, pp. 1741-1753, 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/31729889/.
M. A. Kiebish et al., "Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer," J. Transl. Med., vol. 18, p. 90, 2020. [Online]. Available: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02301-4.
N. A. di Meo et al., "The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery," Expert Rev. Mol. Diagn., vol. 23, no. 4, pp. 297-313, 2023. [Online]. Available: https://www.tandfonline.com/doi/full/10.1080/14737159.2023.1977865.
V. K. Sarhadi and G. Armengol, "Molecular biomarkers in cancer," Biomolecules, vol. 12, no. 6, p. 822, 2022. [Online]. Available: https://www.mdpi.com/2218-273X/12/6/822.
Faubert, A. Solmonson, and R. J. DeBerardinis, "Metabolic reprogramming and cancer progression," Science, vol. 368, no. 6490, pp. 1-8, 2020. [Online]. Available: https://www.nih.gov/science.
L. Xia et al., "The cancer metabolic reprogramming and immune response," Mol. Cancer, vol. 20, p. 37, 2021. [Online]. Available: https://molcan.biomedcentral.com/articles/10.1186/s12885-021-01469-6.
K. Ohshima and E. Morii, "Metabolic reprogramming of cancer cells during tumor progression and metastasis," Metabolites, vol. 11, no. 8, p. 526, 2021. [Online]. Available: https://www.mdpi.com/2218-1989/11/8/526.
E. Janssens, J. P. van Meerbeeck, and K. Lamote, "Volatile organic compounds in human matrices as lung cancer biomarkers: A systematic review," Crit. Rev. Oncol. Hematol., vol. 153, p. 103037, 2020. [Online]. Available: https://www.journals.elsevier.com/critical-reviews-in-oncology-hematology.
J. E. Lewis and M. L. Kemp, "Integration of machine learning and genome-scale metabolic modeling identifies multi-omics biomarkers for radiation resistance," Nat. Commun., vol. 12, p. 4946, 2021. [Online]. Available: https://www.nature.com/articles/s41467-021-25065-x.
Copyright (c) 2025 Mustafa H. Ghazi, Osama A. Mohsein
This work is licensed under a Creative Commons Attribution 4.0 International License.
